Healthcare utilization and total costs of care among patients with advanced metastatic gastric and esophageal cancer
| Autor: | Pranav Abraham, J. Gricar, Hiangkiat Tan, Liya Wang, Ronan J. Kelly, Zhengzheng Jiang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Adolescent Esophageal Neoplasms Newly diagnosed Metastatic gastric cancer Young Adult 03 medical and health sciences 0302 clinical medicine Stomach Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine In patient Aged Retrospective Studies Cisplatin business.industry 030503 health policy & services Health Care Costs General Medicine Middle Aged Patient Acceptance of Health Care Esophageal cancer medicine.disease United States Oncology Healthcare utilization 030220 oncology & carcinogenesis Female Per patient per month 0305 other medical science business Epirubicin medicine.drug |
| Zdroj: | Future Oncology. 17:291-299 |
| ISSN: | 1744-8301 1479-6694 |
| Popis: | Aim: Study first-line (1L) treatment patterns and economic outcomes among patients with advanced metastatic gastric cancer (GC) and esophageal cancer (EC). Materials & methods: Newly diagnosed patients with systemic GC and EC treatments were identified between 1 January 2011 and 31 July 2017; costs were presented as per patient per month (PPPM) basis. Results: Study included 392 GC and 436 EC patients. Most frequently used 1L regimens were: 5-fluorouracil (5-FU) + oxaliplatin (22.5%) and epirubicin + cisplatin + 5-FU (ECF)/ECF modifications (21.9%) in patients with GC; and carboplatin + paclitaxel (29.6%) and 5-FU + oxaliplatin (11.5%) in EC patients. Mean all-cause costs were US$16,242 PPPM for GC, and $18,384 PPPM for EC during 1L treatment. Conclusion: GC and EC were resource intensive and costly. High costs and short treatment durations underscored a gap in care in 1L treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|